scholarly journals Effect of fatty Amazon fish consumption on lipid metabolism

2014 ◽  
Vol 27 (1) ◽  
pp. 97-105 ◽  
Author(s):  
Francisca das Chagas do Amaral Souza ◽  
Nadja Pinto Garcia ◽  
Rejane Souza de Aquino Sales ◽  
Jaime Paiva Lopes Aguiar ◽  
Wallice Luiz Paxiúba Duncan ◽  
...  
Keyword(s):  
Lipid Metabolism ◽  
High Density Lipoprotein ◽  
High Density Lipoprotein Cholesterol ◽  
Amazon Basin ◽  
Density Lipoprotein ◽  
High Density ◽  
Lipoprotein Cholesterol ◽  
Control Group ◽  
Fatty Fish ◽  
Serum Triglycerides

OBJECTIVE: The present study aimed to evaluate the effect of feeding diets enriched with fatty fish from the Amazon basin on lipid metabolism. METHODS: Male Wistar rats were divided into four groups: control group treated with commercial chow; Mapará group was fed diet enriched with Hypophthalmus edentatus; Matrinxã group was fed diet enriched with Brycon spp.; and, Tambaqui group was fed diet enriched with Colossoma macropomum. Rats with approximately 240g±0.60 of body weight were fed ad libitum for 30 days, and then were sacrificed for collection of whole blood and tissues. RESULTS: The groups treated with enriched diets showed a significant reduction in body mass and lipogenesis in the epididymal and retroperitoneal adipose tissues and carcass when compared with the control group. However, lipogenesis in the liver showed an increase in Matrinxã group compared with the others groups. The levels of serum triglycerides in the treated groups with Amazonian fish were significantly lower than those of the control group. Moreover, total cholesterol concentration only decreased in the group Matrinxã. High Density Lipoprotein cholesterol levels increased significantly in the Mapará and Tambaqui compared with control group and Matrinxã group. The insulin and leptin levels increased significantly in all treatment groups. CONCLUSION: This study demonstrated that diets enriched with fatty fish from the Amazon basin changed the lipid metabolism by reducing serum triglycerides and increasing high density lipoprotein-cholesterol in rats fed with diets enriched with Mapará, Matrinxã, and Tambaqui.

scholarly journals Hematology and plasma biochemistry in rats fed with diets enriched with fatty fishes from Amazon region

2014 ◽  
Vol 27 (5) ◽  
pp. 547-555 ◽  
Author(s):  
Francisca das Chagas do Amaral Souza ◽  
Wallice Paxiúba Duncan ◽  
Roasany Piccolotto Carvalho
Keyword(s):  
High Density Lipoprotein ◽  
High Density Lipoprotein Cholesterol ◽  
Density Lipoprotein ◽  
Amazon Region ◽  
High Density ◽  
Lipoprotein Cholesterol ◽  
Control Group ◽  
Standard Diet ◽  
Plasma Biochemistry ◽  
Fatty Fish

OBJECTIVE: Rats fed diets enriched with fatty fish from the Amazon region had Hematology and plasma biochemistry analyzed. METHODS: Forty Wistar rats were divided into four groups: control group fed a standard diet; mapará group fed a diet enriched with Hypophthalmus edentatus; matrinxã group fed a diet enriched with Brycon spp.; and tambaqui group fed a diet enriched with Colossoma macropomum. After thirty days the rats had an red blood count and plasma biochemistry. RESULTS: Hematocrit and hemoglobin levels were higher in rats fed tambaqui and matrinxã than in those fed the standard diet of mapará. However, mapará increased cholesterol, especially low-density lipoprotein cholesterol and high-density lipoprotein cholesterol. All fish-enriched diets reduced triacylglycerols. CONCLUSION: Diets enriched with fatty fish from the Amazon region reduce triacylglycerol and increase high-density lipoprotein cholesterol, especially the diet enriched with tambaqui. Tambaqui and matrinxã affected hematocrit and hemoglobin levels, but not mapará. Further research is needed to determine the benefits of diets enriched with fatty fish from the Amazon region.

Homocysteine and Serum-Lipid Levels in Pulmonary Embolism

2011 ◽  
Vol 17 (6) ◽  
pp. E186-E189 ◽  
Author(s):  
Aysegul Karalezli ◽  
Ebru Sengül Parlak ◽  
Asiye Kanbay ◽  
Aysegul Senturk ◽  
H. Canan Hasanoglu
Keyword(s):  
Pulmonary Embolism ◽  
High Density Lipoprotein ◽  
High Density Lipoprotein Cholesterol ◽  
Serum Lipid ◽  
Density Lipoprotein ◽  
High Density ◽  
Lipoprotein Cholesterol ◽  
Control Group ◽  
Lipid Levels ◽  
Serum Lipid Levels

Pulmonary embolism (PE) is a fatal disease that arises from genetic and environmental factors. There is little evidence for low high-density lipoprotein cholesterol (HDL-C) with hyperhomocysteinemia to lead to PE. Therefore, we evaluated homocysteine levels and lipid profile in PE patients and to display risk for PE. Forty six patients with proven PE and 46 healthy controls were included in the study. Homocysteine and serum lipid levels were calculated and compared in both groups. There were no significant differences between two groups in terms of total cholesterol, triglyceride, and low-density lipoprotein cholesterol. In PE group, HDL-C levels were found significantly lower in comparison to the control group ( P = .004). Mean homocysteine levels were significantly higher in PE group than in the control group ( P = .001). High-density lipoprotein cholesterol levels were significantly low in which homocysteine levels were high in the PE group. We thought that low HDL-C level with hyperhomocysteinemia is susceptible to PE.

scholarly journals Additional Treatment with Fenofibrate for Patients Treated with Pitavastatin under Ordinary Medical Practice for Hypertriglyceridemia in Japan (APPROACH-J Study)

2011 ◽  
Vol 2 ◽  
pp. JCM.S7863 ◽  
Author(s):  
Yasushi Wakida ◽  
Satoshi Suzuki ◽  
Hirohiko Nomura, on behalf of APPROACH-J Investigators ◽  
Tatsuya Isomura
Keyword(s):  
High Density Lipoprotein ◽  
High Density Lipoprotein Cholesterol ◽  
Case Series ◽  
Density Lipoprotein ◽  
Normal Liver ◽  
Additional Treatment ◽  
High Density ◽  
Lipoprotein Cholesterol ◽  
Serious Adverse Events ◽  
Serum Triglycerides

Safety and efficacy of combination therapy of pitavastatin and fenofibrate were examined in consecutive case series with fasting serum triglycerides ≥ 150 mg/dL despite receiving pitavastatin 1 or 2 mg daily for over 2 months and additionally administered micronized fenofibrate 67 mg daily for another 4 to 16 weeks. Such low doses were selected in consideration of safety, and normal liver and renal functions were incorporated in inclusion criteria. In result, a total of 56 cases were examined. The addition of fenofibrate 67 mg to pitavastatin 1 mg/2 mg yielded a 36.8%/35.6% reduction in triglycerides and 6.4%/12.4% elevation in high-density lipoprotein cholesterol, respectively. Almost 70% of the patients achieved triglycerides <150 mg/dL. Statistically significant elevation and decrease were observed in high-density lipoprotein cholesterol level and low-density lipoprotein cholesterol, respectively. Laboratory tests for liver, renal and muscle function statistically significantly elevated after starting fenofibrate co-administration, which were considered comparable to the effect of fenofibrate alone. No myopathy or serious adverse events were reported. In conclusion, while the safety and tolerability need to be further examined over the longer term, and careful monitoring is still needed, this regimen could be considered as one of the treatment option for hypercholesterolemia associated with hypertriglyceridemia.

Sign in / Sign up

Export Citation Format

Share Document